BioNexus Gene Lab Statistics Share Statistics BioNexus Gene Lab has 1.8M
shares outstanding. The number of shares has increased by 1%
in one year.
Shares Outstanding 1.8M Shares Change (YoY) 1% Shares Change (QoQ) 1% Owned by Institutions (%) n/a Shares Floating 1.13M Failed to Deliver (FTD) Shares 178 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 157.34K, so 8.76% of the outstanding
shares have been sold short.
Short Interest 157.34K Short % of Shares Out 8.76% Short % of Float 8.76% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -3.12 and the forward
PE ratio is null.
BioNexus Gene Lab's PEG ratio is
0.08.
PE Ratio -3.12 Forward PE n/a PS Ratio 0.52 Forward PS n/a PB Ratio 0.6 P/FCF Ratio -2.03 PEG Ratio 0.08
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for BioNexus Gene Lab.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.81,
with a Debt / Equity ratio of 0.03.
Current Ratio 3.81 Quick Ratio 3.1 Debt / Equity 0.03 Debt / EBITDA -0.15 Debt / FCF -0.09 Interest Coverage -74.42
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $317.02K Profits Per Employee $-53.28K Employee Count 30 Asset Turnover 0.91 Inventory Turnover 5.92
Taxes Income Tax 3.49K Effective Tax Rate -0.22%
Stock Price Statistics The stock price has increased by 27.25% in the
last 52 weeks. The beta is 1.89, so BioNexus Gene Lab's
price volatility has been higher than the market average.
Beta 1.89 52-Week Price Change 27.25% 50-Day Moving Average 5.45 200-Day Moving Average 3.89 Relative Strength Index (RSI) 53.24 Average Volume (20 Days) 2,046,242
Income Statement In the last 12 months, BioNexus Gene Lab had revenue of 9.51M
and earned -1.6M
in profits. Earnings per share was -0.9.
Revenue 9.51M Gross Profit 1.29M Operating Income -1.57M Net Income -1.6M EBITDA -1.42M EBIT -1.57M Earnings Per Share (EPS) -0.9
Full Income Statement Balance Sheet The company has 4.38M in cash and 210.56K in
debt, giving a net cash position of 4.17M.
Cash & Cash Equivalents 4.38M Total Debt 210.56K Net Cash 4.17M Retained Earnings -3.44M Total Assets 9.42M Working Capital 4.62M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -2.23M
and capital expenditures -226.99K, giving a free cash flow of -2.46M.
Operating Cash Flow -2.23M Capital Expenditures -226.99K Free Cash Flow -2.46M FCF Per Share -1.38
Full Cash Flow Statement Margins Gross margin is 13.56%, with operating and profit margins of -16.55% and -16.81%.
Gross Margin 13.56% Operating Margin -16.55% Pretax Margin -16.77% Profit Margin -16.81% EBITDA Margin -14.94% EBIT Margin -16.55% FCF Margin -25.88%
Dividends & Yields BGLC does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for BGLC.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Apr 7, 2025. It was a
backward
split with a ratio of 1:10.
Last Split Date Apr 7, 2025 Split Type backward Split Ratio 1:10
Scores Altman Z-Score 2.3 Piotroski F-Score 2
